Gano said Ingrezza, now in its eighth year of commercialization, produced $2.51 billion in 2025 revenue, up about 9% year over year, with “double-digit volume growth” and record new prescriptions (NRX) across multiple quarters. He noted a headwind in 2025 related to gross-to-net and net price per script tied to contracts taken on during the year, but said the company expects a “clean year” in 2026 from a contracting and access perspective.On the commercial side, Gano said the company generated “just north o ...

Summary of Neurocrine Biosciences Conference Call Company Overview - **Company**: Neurocrine Biosciences (NasdaqGS:NBIX) - **Date of Conference**: March 17, 2026 - **Key Speakers**: Kyle Gano (CEO), Todd Tushla (Head of IR) Key Points 1. Financial Performance - **2025 Revenue**: Approximately $2.8 billion, representing a **22% year-over-year growth** [4] - **Ingrezza Revenue**: $2.51 billion in 2025, with a **9% year-over-year growth** and double-digit volume growth [5] - **2026 Revenue Guidance**: Expected to be between **$2.7 billion and $2.8 billion** [11] - **Price Trends**: Anticipated **4%-5% price decline** year-over-year for Ingrezza due to expanded access [12] 2. Product Performance - **Ingrezza**: - Eighth year of commercialization with strong sales performance. - Focus on expanding prescriber base, targeting **30% new prescribers** [6] - Anticipated strong year with **double-digit volume growth** [31] - **CRENESSITY**: - First year of commercial sales generated **$300 million** in revenue, capturing **10% of the CH market** [7] - High reimbursement rates with **80% of dispensed scripts reimbursed** [7] - Focus on educational support for physicians and patients to change the standard of care [8] 3. Pipeline and Future Developments - **Phase 3 Trials**: - Osavampator and direclidine expected to deliver data in **2027** [8] - NBI-570 (M1M4 dual agonist) in schizophrenia and NBI-890 (next-generation VMAT2 inhibitor) in phase 2 trials [9][10] - **Next-Generation VMAT2 Program**: - Focus on long-acting injectable formulations to improve patient compliance [72] - **CRF1 Antagonist (NBIP-1435)**: - In phase 1, moving to phase 2/3 later this year, offering a long-acting injectable option [80] 4. Market Dynamics and Competitive Landscape - **Market Access**: - 70% of TD and HD patients under existing contracts, providing a strong market position [36] - **Competitor Analysis**: - Teva's MFP implementation in 2027 and 2028 may impact pricing strategies [36] - **Regulatory Environment**: - Ongoing negotiations with Medicare plans for 2027, with expectations for adjacent MFP products [37] 5. Strategic Focus - **Execution and Data Delivery**: - Emphasis on executing current strategies and delivering data across phase 2 and phase 3 programs in 2027 [10] - **Sustainable Innovation**: - Commitment to a diversified pipeline and innovation engine to support long-term growth [86] 6. Additional Insights - **Patient Compliance**: - Importance of addressing patient reauthorization processes and maintaining access to prescriptions [44] - **Market Sensitivity**: - Anticipation of emotional responses to new patient start forms, with a focus on consistent growth trends [42] Conclusion Neurocrine Biosciences is positioned for continued growth with a strong financial profile, a diversified product portfolio, and a robust pipeline of upcoming clinical data. The company is focused on execution and market access strategies to navigate competitive pressures and regulatory challenges while aiming to enhance patient care through innovative therapies.

Core Insights - Neurocrine Biosciences (NBIX) has successfully demonstrated its business development strategy in 2025, leading to optimism for the company as it enters the first quarter of 2026 [1] Company Performance - The company is positioned in high-growth sectors that are expected to experience exponential expansion [1] - There is a strong focus on disruptive technologies and forward-thinking enterprises, indicating a commitment to innovation [1] Investment Strategy - The approach taken by the company combines fundamental analysis with future trend predictions, aiming to leverage innovation for substantial returns [1]

Core Insights - Neurocrine Biosciences (NBIX) has successfully demonstrated its business development strategy in 2025, leading to optimism for the company as it enters the first quarter of 2026 [1] Company Performance - The company is positioned in high-growth sectors that are expected to experience exponential expansion [1] - There is a strong focus on disruptive technologies and forward-thinking enterprises, indicating a commitment to innovation [1] Investment Strategy - The approach taken by the company combines fundamental analysis with future trend predictions, aiming to leverage innovation for substantial returns [1]

Financial Performance - Neurocrine Biosciences reported fourth-quarter adjusted earnings of $1.88 per share, missing the consensus estimate of $1.89 [1] - Sales reached $805.5 million, exceeding the consensus of $792.47 million [1] - Fourth-quarter net product sales were $798.3 million, reflecting a 29% year-over-year increase [1] Product Sales - Ingrezza's fourth-quarter net product sales were $657.5 million, with full-year 2025 sales at $2.51 billion, showing year-over-year growth of 7% and 9% respectively [1] - Crenessity's fourth-quarter net product sales were $135.3 million, with full-year 2025 sales at $301.2 million, reflecting significant new patient enrollment driven by strong demand and over 80% reimbursement coverage [3] Guidance - The company expects fiscal 2026 Ingrezza product sales to be between $2.70 billion and $2.80 billion [4] Analyst Insights - Analysts note that Neurocrine's stock decline may be due to market reactions to the Ingrezza guidance, which was already anticipated [5] - Analyst Myles Minter views any volatility as a buying opportunity, emphasizing a longer-term positive outlook for the company despite a lighter clinical catalyst year in 2026 [5] - An Outperform rating on Neurocrine has been reiterated by analysts [6]

Neurocrine Biosciences FY Conference Summary Company Overview - **Company**: Neurocrine Biosciences (NasdaqGS:NBIX) - **Event**: 44th Annual J.P. Morgan Healthcare Conference - **Date**: January 12, 2026 - **Key Speaker**: Kyle Gano, CEO Core Themes 1. **Strong and Building Momentum** - Neurocrine has a workforce of 2,000 and a proven track record in discovering, developing, and commercializing medicines for patients [2][3] - The company has four FDA-approved medicines, including Ingrezza and Crinecerfont, which are marketed in the U.S. [3] - In 2025, Ingrezza is projected to generate $2.5-$2.55 billion in net sales, while Crinecerfont achieved $166 million in net sales in its first nine months [4] 2. **Strategic Balanced Diversification** - Transitioned from a single product company focused on small molecules to a diversified biopharmaceutical company [5][6] - Crinecerfont is expected to be a significant contributor to revenue diversification alongside Ingrezza [6] - The company is expanding its R&D efforts into new therapeutic areas, including peptides, antibodies, and gene therapies [7][8] Financial Performance - **Ingrezza**: Projected net sales of $2.5-$2.55 billion for 2025 [4] - **Crinecerfont**: $166 million in net sales for the first nine months of commercialization [4] R&D Pipeline - **Current Pipeline**: 12 programs in clinical development (8 in phase one, 2 in phase two, 2 in phase three) [35] - **Goals**: Targeting four new phase one programs and advancing two new phase two programs annually [11] - **Focus Areas**: Neurology, psychiatry, endocrinology, with a strong emphasis on validated biology [35] Key Products and Programs 1. **Crinecerfont**: - First approved treatment for classic congenital adrenal hyperplasia (CAH) [41] - Positive two-year data showing robust efficacy and safety, with an 80% retention rate in the open-label extension study [24][45] - 40% of patients experienced a 5% or greater weight loss during the two-year period [25] 2. **Neuropsychiatry Portfolio**: - Includes first-in-class AMPA PAM for major depressive disorder and Derecladine for schizophrenia [13][14] - Both programs are in phase three trials, with potential to change the standard of care [37] 3. **Emerging Endocrinology Pipeline**: - Focused on CRF biology, with programs targeting obesity and metabolic disorders [17][19] - New molecule MBIP2118 for obesity is set to be a once-weekly injectable with a differentiated product profile [19] Market Strategy - **Sales Force Expansion**: Aiming to deepen engagement with endocrinologists and reach patients not currently under specialized care [48] - **Reimbursement Success**: Patients have been able to secure commercial reimbursement within a week, exceeding initial expectations [43] Safety and Efficacy - Crinecerfont has shown a favorable safety profile with no new safety warnings and a low rate of adrenal insufficiency [49][50] - Long-term steroid reduction has led to improvements in weight loss and insulin resistance, critical for patients with CAH [50] Future Outlook - Anticipated data flow from various programs, including gene therapy for Friedreich's Ataxia and weight loss data from CRF2 peptide studies [38] - Continued focus on building a robust R&D engine to support future growth and innovation [36] Conclusion - Neurocrine is positioned for significant growth in 2026 and beyond, with a strong pipeline and strategic diversification efforts aimed at enhancing patient care and expanding market reach [9][10]

Neurocrine Biosciences 2025 R&D Day Summary Company Overview - **Company**: Neurocrine Biosciences (NasdaqGS:NBIX) - **Event**: 2025 R&D Day held on December 16, 2025 - **Key Speakers**: - Kyle Gano, Chief Executive Officer - Sanjay Keswani, Chief Medical Officer - Jude Onyia, Chief Scientific Officer - Dr. John Krystal, expert in neurology and psychiatry Core Industry Insights - **Transition**: Neurocrine is evolving from a single-product biotech to a multi-product diversified biopharmaceutical company with scale [11] - **Employee Base**: The company has grown to 2,000 employees, consolidating all departments under one roof for enhanced collaboration [11][6] - **R&D Focus**: Emphasis on innovative science and pipeline development, particularly in neuropsychiatry [8] Key Products and Pipeline - **Current Products**: - Ingrezza (for tardive dyskinesia) - Krenesti (for CAH) - **Future Products**: - Osirvampetor (for major depressive disorder) - Direclidine (for schizophrenia) - **Pipeline Strategy**: Focus on delivering multiple best-in-class medicines by 2030, leveraging a transformed R&D engine [12][16] R&D Transformation - **R&D Engine**: Fully operational and over-delivering on innovative science, with a focus on high-quality programs across various modalities [12][13] - **CRF Biology**: Leveraging 30 years of expertise in corticotropin-releasing factor (CRF) biology to expand into metabolic disorders, including obesity [14] - **Clinical Trials**: Anticipated phase three trials for Osirvampetor and Direclidine to start reading out in 2027 [16] Market Opportunity - **Mental Health Crisis**: Over one-third of individuals with depression do not respond to current treatments, highlighting a significant unmet need [45] - **Safety and Tolerability**: Osirvampetor aims to provide ketamine-like efficacy without the associated safety issues, such as psychotomimetic effects [40][46] Competitive Advantages - **Institutional Knowledge**: Deep expertise in neurology, psychiatry, endocrinology, and immunology, providing a competitive edge in drug development [19][20] - **Business Development**: Active role in partnerships to enhance R&D capabilities and fill pipeline gaps [31] Future Outlook - **Investment in R&D**: Strong financial profile allows for continued investment in R&D across therapeutic areas [26] - **Execution and Innovation**: Commitment to execution and repeatable innovation as key drivers for future success [36][37] Conclusion Neurocrine Biosciences is positioned for significant growth and innovation in the biopharmaceutical space, particularly in neuropsychiatry, with a robust pipeline and a commitment to addressing unmet medical needs in mental health. The company's strategic focus on leveraging its institutional knowledge and transforming its R&D capabilities is expected to yield multiple new therapies by the end of the decade [11][12][16].

Group 1: Market Performance - Israel's stock market has outperformed the U.S. market since October 7, 2023, with significant gains in U.S.-traded companies such as Teva Pharmaceutical, Elbit Systems, and Tower Semiconductor [5] Group 2: Company Highlights - Neurocrine Biosciences (NBIX) is highlighted as a key stock to watch, currently within a 5% buy zone from a recent entry, with flagship drugs including Crenessity for congenital adrenal hyperplasia and Ingrezza for movement disorders [6][10] - Neurocrine Biosciences has seen its Relative Strength Rating rise to 82, indicating improved market performance [7][10] - Despite a strong quarterly performance, Neurocrine's stock experienced volatility, reflecting market reactions to broader industry trends [10] Group 3: Industry Insights - The top money manager emphasizes the need for investors to return to realistic expectations, noting that while companies like Nvidia and Palantir are currently underperforming, there is significant interest in AI-related investments [8]

Summary of Neurocrine Biosciences FY Conference Call Company Overview - **Company**: Neurocrine Biosciences (NasdaqGS:NBIX) - **Date**: December 02, 2025 - **Key Speakers**: Matt Abernethy (CFO), Eric Benevich (Chief Commercial Officer), Todd Tushla (Director of Investor Relations) Core Industry Insights - The biotech industry has faced significant challenges over the past year, but Neurocrine has executed well despite these difficulties [8][10][26] - The company is focused on helping patients with conditions like tardive dyskinesia and congenital adrenal hyperplasia (CAH) [10][14] Key Products and Financial Performance - **Ingrezza**: - Generated approximately $2.5 billion in revenue this year [11] - Only 10% of patients with tardive dyskinesia are currently treated with VMAT2 inhibitors, indicating substantial growth potential [12][62] - **Crinecerfont**: - Approved for CAH, with no approved treatment options for over 70 years [14] - One year post-launch, the company has reached 10% of the CAH patient population [16][94] Strategic Challenges and Responses - The company is navigating the implications of the Inflation Reduction Act (IRA) and believes it can manage the impact on Ingrezza from 2027 to 2029 [22][61] - Neurocrine aims to increase its market cap beyond $20 billion, currently positioned between $10-$20 billion [26][28] Market Position and Competitive Landscape - The company has a strong cash position of $2 billion with no debt, allowing for potential business development opportunities [28] - The competitive landscape includes recent acquisitions in the psych space, but Neurocrine is focused on internal development and leveraging its commercial infrastructure [56][58] Sales and Marketing Strategy - The company is expanding its sales force to include advanced practice providers, which are now the largest group of prescribers for VMAT2 medications [90][92] - The expansion is driven by double-digit growth in the VMAT2 category, with Ingrezza growing faster than the overall category [89] Future Outlook - The company is optimistic about the continued growth of Ingrezza and Crinecerfont, with plans to maintain formulary coverage and negotiate favorable pricing with Medicare [62][67] - Upcoming R&D day is anticipated to provide further insights into the company's pipeline and strategic direction [108][111] Additional Considerations - The company emphasizes patient-centric approaches and aims to increase awareness and treatment rates for tardive dyskinesia and CAH [62][90] - The management team is committed to maximizing the value of existing products while exploring new opportunities in neuro and endocrine spaces [58][44]

Core Insights - Novo Nordisk's stock rose due to a lighter-than-expected discount for its semaglutide-based products, Ozempic and Wegovy, under the Inflation Reduction Act, with discounts ranging from 38% to 85% [1][3] - The Centers for Medicare and Medicaid Services (CMS) estimates that price negotiations will save patients $685 million in out-of-pocket costs, focusing on the 15 most expensive drugs in Medicare [2] - Teva Pharmaceutical's Austedo received a 38% discount, with projected sales of $2.5 billion in 2027, contributing to a 4% rise in its stock [5][6] Novo Nordisk - Semaglutide will face a 71% discount, reducing its Medicare price to $274 per month in 2027 from a list price of $959 in 2024 [3] - The discount aligns with a Most Favored Nation deal, allowing Medicare to cover obesity drugs for the first time [4] - Novo Nordisk's stock is currently trading below key moving averages, indicating potential pressure [9] Teva Pharmaceutical - Teva's Austedo will see its price drop from $6,623 to $4,093 by 2027, leading to a positive outlook for the drug [5] - Teva's stock increased by over 4% following the news, reflecting investor confidence [6] AstraZeneca and BeOne Medicines - AstraZeneca's Calquence faces a 40% discount, dropping from $14,228 to $8,600 per month by 2027, but is not expected to significantly impact its market position against BeOne's Brukinsa [7][8] - BeOne's stock rose more than 2%, indicating a favorable market response despite AstraZeneca's discount [8]